StockData

NuCana plc (NCNA) stock

NCNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 19, 2026Score 1/30
$0.86−0.07 (-7.19%)

Close on Nov 16, 2026Market cap $3.59MP/E –Yield –

NuCana cash

Cash and short-term investments held at the end of each period.

NuCana's cash was £19.50M at Jun 30, 2026. For fiscal 2025 it was £24.25M, up 259.3% from the year before. Over ten years it grew 5.6% a year on average. The highest annual figure on record is £87.36M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025£24.25M+259.3%
FY2024Dec 31, 2024£6.75M-60.8%
FY2023Dec 31, 2023£17.23M-58.9%
FY2022Dec 31, 2022£41.91M-30.5%
FY2021Dec 31, 2021£60.26M-31.0%
FY2020Dec 31, 2020£87.36M+68.1%
FY2019Dec 31, 2019£51.96M-32.5%
FY2018Dec 31, 2018£76.97M-11.2%
FY2017Dec 31, 2017£86.70M+333.7%
FY2016Dec 31, 2016£19.99M+41.7%
FY2015Dec 31, 2015£14.11M-24.8%
FY2014Dec 31, 2014£18.76M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026£19.50M+67.6%
Q4 FY2025Dec 31, 2025£24.25M+40.8%
Q2 FY2025Jun 30, 2025£8.44M-65.7%
Q4 FY2024Dec 31, 2024£6.75M-83.9%
Q2 FY2024Jun 30, 2024£11.64M-75.0%
Q4 FY2023Dec 31, 2023£17.23M-71.4%
Q2 FY2023Jun 30, 2023£24.64M-65.3%
Q4 FY2022Dec 31, 2022£41.91M-42.9%
Q2 FY2022Jun 30, 2022£46.53M-40.8%
Q4 FY2021Dec 31, 2021£60.26M-31.0%
Q3 FY2021Sep 30, 2021£71.03M-29.5%
Q2 FY2021Jun 30, 2021£73.42M+53.6%
Q1 FY2021Mar 31, 2021£78.63M+65.2%
Q4 FY2020Dec 31, 2020£87.36M+68.1%
Q3 FY2020Sep 30, 2020£100.68M+73.3%
Q2 FY2020Jun 30, 2020£47.80M-26.7%
Q1 FY2020Mar 31, 2020£47.60M-31.9%
Q4 FY2019Dec 31, 2019£51.96M-32.5%
Q3 FY2019Sep 30, 2019£58.09M-25.9%
Q2 FY2019Jun 30, 2019£65.17M-20.0%
Q1 FY2019Mar 31, 2019£69.91M-14.1%
Q4 FY2018Dec 31, 2018£76.97M-11.2%
Q3 FY2018Sep 30, 2018£78.35M+517.8%
Q2 FY2018Jun 30, 2018£81.47M+411.8%
Q1 FY2018Mar 31, 2018£81.34M+306.9%
Q4 FY2017Dec 31, 2017£86.70M+514.4%
Q3 FY2017Sep 30, 2017£12.68M-32.4%
Q2 FY2017Jun 30, 2017£15.92M–
Q4 FY2016Dec 31, 2016£19.99M–
Q4 FY2015Dec 31, 2015£14.11M–
Q4 FY2014Dec 31, 2014£18.76M–

More NuCana figures

See a number that looks wrong?